Pharmacokinetics of cisapride in the horse.
The purpose of this study was to determine the pharmacokinetics and absolute bioavailability of cisapride after intravenous (i.v.) and intragastric (i.g.) administration in healthy, adult horses. Five animals received single doses of 0.1 mg/kg, 0.2 mg/kg and 0.4 mg/kg cisapride by the i.g. route in an open, randomized fashion on different occasions separated by a washout period of at least 48 h. Four of these horses were also given a single i.v. dose of 0.1 mg/kg cisapride. Jugular venous blood was collected periodically up to 24 h after dosing. Plasma cisapride concentrations were measured by high-performance liquid chromatography. There was considerable inter individual variability in pharmacokinetic parameters. The mean (SD) values for systemic clearance (CI) and steady-state volume of distribution (Vss) were 494 (43.6) mL/h/kg and 1471 (578) mL/kg, respectively. Although the rate of cisapride absorption was quite rapid, only about half the i.g. dose was absorbed systemically. The average terminal half-life (t1/2) calculated over three i.g. doses was 2.06 h and that for i.v. administration was 2.12 h. The pharmacokinetics of cisapride from 0.1 mg/kg to 0.4 mg/kg were independent of the i.g. dose.
Steel
C M
CM
Department of Applied Veterinary Medicine, Murdoch University, Western Australia, Australia.
Bolton
J R
JR
Preechagoon
Y
Y
Charles
B G
BG
D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D020117:Cisapride / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006736:Horses / Q000097:blood / Q000378:metabolism*; D007275:Injections, Intravenous / Q000662:veterinary; D007441:Intubation, Gastrointestinal / Q000662:veterinary; D008297:Male; D011897:Random Allocation
D000897:Anti-Ulcer Agents; D020117:Cisapride